A phase I, randomised, double-blind, placebo-controlled, parallel-group, single-centre study to investigate the safety, tolerability and pharmacokinetics of multiple ascending doses of AZD3199 (a β2-agonist ) given once daily as inhaled formulation via Turbuhaler to healthy men
